UK Centre for Tobacco Control Studies, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary, University of London, London Newark Street, London E1 2AT, UK.
BMC Med. 2013 May 29;11:140. doi: 10.1186/1741-7015-11-140.
Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.
117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12 weeks. Participants lost to follow-up were included as continuing smokers.
92% of participants used both medications during the first week after the TQD. The combination treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS).
The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further trials would be useful to exclude the possibility of type II error.
Clinicaltrials.gov
NCT01184664.
尼古丁替代疗法(NRT)和伐伦克林都有助于帮助吸烟者戒烟。人们对联合使用这两种治疗方法以提高治疗效果越来越感兴趣,但目前尚无关于这种联合治疗是否有效的实验数据。本双盲随机对照试验旨在评估在伐伦克林的基础上加用尼古丁贴片是否能改善戒断缓解和短期戒烟率。
117 名寻求戒烟帮助的参与者被随机分配至伐伦克林加安慰剂贴片或伐伦克林加尼古丁贴片(15mg/16 小时)组。在目标戒烟日(TQD)前一周开始使用伐伦克林,TQD 当天开始使用贴片。在 TQD 后 4 周每周收集一次吸烟欲望和香烟戒断症状的评分。在 1、4 和 12 周时评估药物使用和吸烟状况。失访者被视为继续吸烟者。
92%的参与者在 TQD 后第一周内同时使用了两种药物。联合治疗并未增加恶心或其他不良反应。它对吸烟欲望或其他戒断症状均无总体影响。联合治疗并未提高 TQD 后 1 周和 4 周时的生物化学验证戒烟率(尼古丁贴片组为 69% vs 59%,p=0.28;安慰剂贴片组为 60% vs 59%,p=0.91),也未提高 TQD 后 12 周时的自我报告戒烟率(尼古丁贴片组为 36% vs. 29%,p=0.39,NS)。
在伐伦克林的基础上加用尼古丁贴片并未增强其疗效,尽管进一步的试验可能有助于排除二类错误的可能性。
Clinicaltrials.gov
NCT01184664